This menu provides the list of EV proteins identified by high-throughput analyses.
Refresh all contents
Search:
Dataset accession
UniProt accession
UniProt name
Protein name
Gene symbol
Species
Orthologous group
Superdomain:
All
Prokaryote
Eukaryote
Filter datasets:
- "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
- "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
By species
Homo sapiens
Mus musculus
In vitro/In vivo
Ex vivo
In vitro
In vivo
By sample type
Amnion epithelial cell
Amniotic fluid
Amniotic fluid stem cell
Aqueous humor of age-related macular degeneration
Ascites
B cell (RN (HLA-DR15))
Blood
Bone marrow aspirate
Bone marrow stromal cell
Bone marrow-derived mesenchymal stem cell (MSC)
Brain
Breast cancer cell (BT549)
Breast cancer cell (HS 578T)
Breast cancer cell (MCF-7)
Breast cancer cell (MCF7)
Breast cancer cell (MDA-MB-231)
Breast cancer cell (MDA-MB-468)
Breast cancer cell (T-47D)
Breast milk
Bronchial epithelial cell (30KT)
Carotid atherosclerotic plaque
Central nervous system cancer cell (SF268)
Central nervous system cancer cell (SF295)
Central nervous system cancer cell (SF539)
Central nervous system cancer cell (SNB-19)
Central nervous system cancer cell (SNB-75)
Central nervous system cancer cell (U251)
Cerebrospinal fluid
Cervical cancer (HeLa)
Choriocarcinoma cell (JEG3)
Chronic lymphoid leukemia cell (MEC-1)
Chronic myeloid leukemia (K562)
Colon cancer cell (Colo205)
Colon cancer cell (HCC 2998)
Colon cancer cell (HCT-116)
Colon cancer cell (HCT-15)
Colon cancer cell (HT29)
Colon cancer cell (KM12)
Colon cancer cell (SW480)
Colon cancer cell (SW620)
Colorectal cancer cell (HT29)
Colorectal cancer cell (LIM1215)
Colorectal cancer cell (SW480)
Colorectal cancer cell (SW620)
Colorectal cancer cells (HCT116, DLD1, SW480, SW620)
Dendritic cell
Dermal fibroblast (HDF)
Embryonic kidney cell (293T)
Embryonic kidney cell (HEK293)
Embryonic kidney cell (HEK293T)
Embryonic kidney cells (293T)
Embryonic stem cell derived mesenchymal stem cell
Endothelial cell (HMEC-1)
Endothelial progenitor cell
Epithelial ovarian carcinoma cell (OVCAR3, OVCAR433, OVCAR5 , SKOV3)
Erythrocyte
Expressed prostatic secretions in urine
Extravillous trophoblast cell (HTR8/SVneo)
Glioblastoma cell (U87)
Hepatic stellate cell
Hepatocellular carcinoma cell (Hep3B)
Hepatocellular carcinoma cell (Huh7)
Hepatocellular carcinoma cell (LM3)
Hepatoma cell (Huh-7)
Keratinocyte
Kidney cancer cell (786-O)
Kidney cancer cell (A498)
Kidney cancer cell (ACHN)
Kidney cancer cell (CAKI)
Kidney cancer cell (RXF 393)
Kidney cancer cell (SN12C)
Kidney cancer cell (TK-10)
Kidney cancer cell (UO-31)
Leukemia cell (CCRF-CEM)
Leukemia cell (HL-60)
Leukemia cell (K562)
Leukemia cell (MOLT-4)
Leukemia cell (RPMI-8226)
Leukemia cell (SR)
Leukopak
Lung cancer cell (A549)
Lung cancer cell (HOP-62)
Lung cancer cell (HOP-92)
Lung cancer cell (NCI-H226)
Lung cancer cell (NCI-H23)
Lung cancer cell (NCI-H322M)
Lung cancer cell (NCI-H460)
Lung cancer cell (NCI-H522)
Lung cancer pleural effusion
Lung epithelial cell (E10)
Macrophage
Macrophage (THP1)
Mammary epithelial cell (MCF10A)
Melanocyte
Melanoma cell (1205Lu)
Melanoma cell (501mel)
Melanoma cell (A375M)
Melanoma cell (B16-F10, SK-MEL-202, SK-MEL035, SK-MEL-265)
Melanoma cell (Daju)
Melanoma cell (G1)
Melanoma cell (LOX IMVI)
Melanoma cell (M14)
Melanoma cell (MALME-3M)
Melanoma cell (MDA-MB-435)
Melanoma cell (MNT-1)
Melanoma cell (SK-MEL-2)
Melanoma cell (SK-MEL-28)
Melanoma cell (SK-MEL-5)
Melanoma cell (SKMEL28)
Melanoma cell (UACC-257)
Melanoma cell (UACC-62)
Mesenchymal stem cell
Mesothelioma cell (JO38)
Middle-ear epithelial cell (HMEEC-1)
Monocyte (THP-1)
Monocyte-derived macrophage
Monocyte-derived macrophages
Nasal lavage
Neonatal myoblast cell
Neuroblastoma cell (CHLA255)
Neuroblastoma cell (HTLA-230)
Neuroblastoma cell (IGR-N91)
Neuroblastoma cell (IGR-NB8)
Neuroblastoma cell (IMR32)
Neuroblastoma cell (LAN-1)
Neuroblastoma cell (SH-SY5Y)
Neuroblastoma cell (SK-N-SH)
Neuroblastoma cell (SKNBe2c)
Neutrophil
Non small cell lung cancer (A549)
Non small cell lung cancer (HCC827)
Normal B cell (BJAB)
Normal bronchial epithelial cell (HBE4)
Oral squamous cell carcinoma cell (BHY)
Osteosarcoma cell (MG63)
Osteosarcoma cell (SAOS-2)
Osteosarcoma cell (U2OS)
Ovarian cancer (OVCA429)
Ovarian cancer cell (IGROV1)
Ovarian cancer cell (NCI-ADR-RES)
Ovarian cancer cell (OVCAR-3)
Ovarian cancer cell (OVCAR-4)
Ovarian cancer cell (OVCAR-5)
Ovarian cancer cell (OVCAR-8)
Ovarian cancer cell (SK-OV-3)
Pancreatic ductal adenocarcinoma cell (Pa03C)
Pancreatic ductal adenocarcinoma cell (Pa21C)
Pancreatic ductal adenocarcinoma cell (Pa28C)
Pancreatic ductal epithelial cell (HPNE)
Peritoneal dialysis effluent
Placental mesenchymal stem cell
Placental villous tissue
Plasma
Platelet
Platelet-poor plasma
Prostate cancer cell (DU145)
Prostate cancer cell (DuCaP)
Prostate cancer cell (LNCaP)
Red blood cell
Retinal pigment epithelial cell (RPE-1)
Seminal plasma
Serum
T cells (ED40515(-))
Thymus
Urinary bladder transitional cell carcinoma (FL3)
Urinary bladder transitional cell carcinoma (SLT4)
Urinary bladder transitional cell carcinoma (T24)
Urine
W8B2+ cardiac stem cell
Whole blood
By sample status
Androgen-deprived
Bioreactor culture
Breast cancer-bronchiectasis non-tuberculosis Mycobacterium-infected
Bronchiectasis non-tuberculosis Mycobacterium-infected
CD63-CRISPR
CHAPS-treated
Cell-mediated rejection
Centrifugation
Cholera toxin B-bound
Cholera toxin B-depleted
Chondroitin sulfate-treated
Cocultured with C. albicans
Colorectal cancer
Control
Control_24 h
Control_48 h
Curcumin-treated
Cystinuria patients, molecular weight fractionation
Cystinuria patients, pI fractionation
DTT-treated
Deoxyelephantopin (DET)-treated
Deoxyelephantopin derivative-35 (DETD-35)-treated
Differentiated
Dihydrotestosterone-treated
Docetaxel-resistant
Docetaxel-sensitive
Donor 1 (Exo-Spin)
Donor 1 (SEC fraction 7+8)
Donor 2 (Exo-Spin)
Donor 3 (Exo-Spin)
Donor 3 (SEC fraction 8)
Doxorubicin-treated
Exosomes
F3-10K
F5-100K
F5-10K
Flask culture
HIV-1-infected_Exosome
HTLV-1-infected, Tax-negative
Healthy
Helicobacter pylori-infected
High-grade bladder cancer
High-risk prostate cancer (Gleason score 8-9)
Hypertensive patients under chronic suppression of RAS
Hypoxic condition
IL3-Lamp2b-transfected
Idiopathic longitudinally extensive transverse myelitis
Influenza A virus-infected
Insulin-induced
Irradiated (6 Gy)
Lacunar infarction-cognitive decline without recurrent vascular events
Lacunar infarction-no adverse outcome
Lacunar infarction-recurrent vascular events
Low-grade prostate cancer patient
Low-risk prostate cancer (Gleason score 6)
Low-sulfated hyaluronic acid-treated
M. tuberculosis-infected
Mature milk
Microvesicle, Storage day 3
Microvesicles
Multiple myeloma
Multiple sclerosis
Mycobacterium tuberculosis-infected_Orbitrap
Mycobacterium tuberculosis-infected_QSTAR
Nanovesicle, Storage day 21
Nanovesicle, Storage day 3
Nanovesicle, Storage day 42
Neuromyelitis optica
Non-small cell lung cancer patient
Non-sulfated hyaluronic acid-treated
Nontypeable Haemophilus influenzae lysate-treated_24 h
Nontypeable Haemophilus influenzae lysate-treated_48 h
Normal
Normal donors
Normal donors and patients of deep venous thrombosis
Normal_Annexin V-binding EVs
Normal_Orbitrap
Normal_QSTAR
Normal_Ultracentrifugation
Oxidative stress
P. falciparum-infected
PDGF-BB-treated
PEG precipitation
Parkinson's disease patient
Patient of developmental heart defect_exosome
Patient of developmental heart defect_microparticle
Patients of basement membrane nephropathy
Patients of bladder cancer
Patients of carotid atherosclerosis
Patients of colorectal cancer
Patients of external counterpulsation therapy
Preeclampsia patients
Preeclampsia_Annexin V-binding EVs
Preeclampsia_Cholera toxin part B-binding EVs
Protein organic solvent precipitation
Radiation
ST-eleavated myocardial infarction
Size exclusion chromatography
Stimulated by IgG
Stimulated in immobile phase
Stimulated with beta-glucan
Stressed (hypoxia, TNF-慣-induced activation, high glucose and mannose concentrations)
TGF-β-treated
Trauma patients
Tubular injury
Ultra-cushion
Ultracentrifugation
p53 knock-down and EGFR L858R point mutation
pCMV-HA-HBx-transfected
pCMV-HBV1.1(X')-transfected
pCMV-HBV1.1-transfected
pCMV-transfected
Number of molecules in one page:
100
200
All
The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.
Protein name
UniProt accession
Publication
Orthologous group
Identification count
All / Prokaryote / Eukaryote
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers.
Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13569.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.
Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14964.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.
Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14964.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.
Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14964.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.
Sci Rep. 2017 Feb 17;7:42961. doi: 10.1038/srep42961.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.
Sci Rep. 2017 Feb 17;7:42961. doi: 10.1038/srep42961.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.
Sci Rep. 2017 Feb 17;7:42961. doi: 10.1038/srep42961.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.
Sci Rep. 2017 Feb 20;7:42741. doi: 10.1038/srep42741.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.
Sci Rep. 2017 Feb 20;7:42741. doi: 10.1038/srep42741.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative changes in the protein and miRNA cargo of plasma exosome-like vesicles after exposure to ionizing radiation.
Int J Radiat Biol. 2017 Mar 7:1-12. doi: 10.1080/09553002.2017.1294772.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative changes in the protein and miRNA cargo of plasma exosome-like vesicles after exposure to ionizing radiation.
Int J Radiat Biol. 2017 Mar 7:1-12. doi: 10.1080/09553002.2017.1294772.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment.
J Extracell Vesicles. 2016 Dec 23;6(1):1267896. doi: 10.1080/20013078.2016.1267896. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Theranostics. 2017 Mar 16;7(5):1333-1345. doi: 10.7150/thno.17092. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Theranostics. 2017 Mar 16;7(5):1333-1345. doi: 10.7150/thno.17092. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Differential protein expression in exosomal samples taken from trauma patients.
Proteomics Clin Appl. 2017 May 25. doi: 10.1002/prca.201700061.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.
Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17787.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2.
Nat Commun. 2017 Jun 6;8:15729. doi: 10.1038/ncomms15728.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2.
Nat Commun. 2017 Jun 6;8:15729. doi: 10.1038/ncomms15728.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.
Proteomics. 2017 Jun 7. doi: 10.1002/pmic.201700103.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Motile hepatocellular carcinoma cells preferentially secret sugar metabolism regulatory proteins via exosomes.
Proteomics. 2017 Jun 7. doi: 10.1002/pmic.201700103.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers.
PLoS One. 2017 Jun 8;12(6):e0178601. doi: 10.1371/journal.pone.0178601. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers.
PLoS One. 2017 Jun 8;12(6):e0178601. doi: 10.1371/journal.pone.0178601. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity.
Sci Rep. 2017 Jul 5;7(1):4711. doi: 10.1038/s41598-017-05002-y.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity.
Sci Rep. 2017 Jul 5;7(1):4711. doi: 10.1038/s41598-017-05002-y.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions.
Front Pharmacol. 2017 Jun 29;8:398. doi: 10.3389/fphar.2017.00398. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions.
Front Pharmacol. 2017 Jun 29;8:398. doi: 10.3389/fphar.2017.00398. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions.
Front Pharmacol. 2017 Jun 29;8:398. doi: 10.3389/fphar.2017.00398. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method.
J Extracell Vesicles. 2017 Apr 28;6(1):1313091. doi: 10.1080/20013078.2017.1313091. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method.
J Extracell Vesicles. 2017 Apr 28;6(1):1313091. doi: 10.1080/20013078.2017.1313091. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method.
J Extracell Vesicles. 2017 Apr 28;6(1):1313091. doi: 10.1080/20013078.2017.1313091. eCollection 2017.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600432.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600432.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Insulin mediated activation of PI3K/Akt signalling pathway modifies the proteomic cargo of extracellular vesicles.
Proteomics. 2017 Aug 26. doi: 10.1002/pmic.201600371.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Comprehensive proteomics analysis of exosomes derived from human seminal plasma.
Andrology. 2017 Sep;5(5):1007-1015. doi: 10.1111/andr.12412.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells.
Sci Rep. 2017 Sep 29;7(1):12423. doi: 10.1038/s41598-017-12403-6.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells.
Sci Rep. 2017 Sep 29;7(1):12423. doi: 10.1038/s41598-017-12403-6.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics.
Sci Rep. 2017 Oct 6;7(1):12782. doi: 10.1038/s41598-017-13092-x.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics.
Sci Rep. 2017 Oct 6;7(1):12782. doi: 10.1038/s41598-017-13092-x.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Nontypeable Haemophilus influenzae lysates increase heterogeneous nuclear ribonucleoprotein secretion and exosome release in human middle-ear epithelial cells.
FASEB J. 2017 Nov 30. pii: fj.201700248RR. doi: 10.1096/fj.201700248RR.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Nontypeable Haemophilus influenzae lysates increase heterogeneous nuclear ribonucleoprotein secretion and exosome release in human middle-ear epithelial cells.
FASEB J. 2017 Nov 30. pii: fj.201700248RR. doi: 10.1096/fj.201700248RR.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Nontypeable Haemophilus influenzae lysates increase heterogeneous nuclear ribonucleoprotein secretion and exosome release in human middle-ear epithelial cells.
FASEB J. 2017 Nov 30. pii: fj.201700248RR. doi: 10.1096/fj.201700248RR.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Nontypeable Haemophilus influenzae lysates increase heterogeneous nuclear ribonucleoprotein secretion and exosome release in human middle-ear epithelial cells.
FASEB J. 2017 Nov 30. pii: fj.201700248RR. doi: 10.1096/fj.201700248RR.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Tetraspanin CD63 bridges autophagic and endosomal processes to regulate exosomal secretion and intracellular signaling of Epstein-Barr virus LMP1.
J Virol. 2017 Dec 6. pii: JVI.01969-17. doi: 10.1128/JVI.01969-17.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Tetraspanin CD63 bridges autophagic and endosomal processes to regulate exosomal secretion and intracellular signaling of Epstein-Barr virus LMP1.
J Virol. 2017 Dec 6. pii: JVI.01969-17. doi: 10.1128/JVI.01969-17.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Amniotic fluid stem cell exosomes: Therapeutic perspective.
Biofactors. 2018 Jan 16. doi: 10.1002/biof.1407.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Amniotic fluid stem cell exosomes: Therapeutic perspective.
Biofactors. 2018 Jan 16. doi: 10.1002/biof.1407.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Biologically active constituents of the secretome of human W8B2(+) cardiac stem cells.
Sci Rep. 2018 Jan 25;8(1):1579. doi: 10.1038/s41598-018-19855-4.
ENOG4111MYC
347
/
0
/
347
<
[3]